[go: up one dir, main page]

EE05129B1 - Konjugeeritud ”strogeenide ja medroksprogesteroonatsetaadi kasutamine, farmatseutiline kompositsioon, doseerimishik ja pakend - Google Patents

Konjugeeritud ”strogeenide ja medroksprogesteroonatsetaadi kasutamine, farmatseutiline kompositsioon, doseerimishik ja pakend

Info

Publication number
EE05129B1
EE05129B1 EEP200200535A EEP200200535A EE05129B1 EE 05129 B1 EE05129 B1 EE 05129B1 EE P200200535 A EEP200200535 A EE P200200535A EE P200200535 A EEP200200535 A EE P200200535A EE 05129 B1 EE05129 B1 EE 05129B1
Authority
EE
Estonia
Prior art keywords
medrox
strogens
conjugated
package
pharmaceutical composition
Prior art date
Application number
EEP200200535A
Other languages
English (en)
Inventor
Harrison Pickar James
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26886279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05129(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth filed Critical Wyeth
Publication of EE200200535A publication Critical patent/EE200200535A/et
Publication of EE05129B1 publication Critical patent/EE05129B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
EEP200200535A 2000-03-20 2001-03-16 Konjugeeritud ”strogeenide ja medroksprogesteroonatsetaadi kasutamine, farmatseutiline kompositsioon, doseerimishik ja pakend EE05129B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19063000P 2000-03-20 2000-03-20
US26860701P 2001-02-14 2001-02-14
PCT/US2001/040302 WO2001070208A2 (en) 2000-03-20 2001-03-16 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate

Publications (2)

Publication Number Publication Date
EE200200535A EE200200535A (et) 2004-04-15
EE05129B1 true EE05129B1 (et) 2009-02-16

Family

ID=26886279

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200535A EE05129B1 (et) 2000-03-20 2001-03-16 Konjugeeritud ”strogeenide ja medroksprogesteroonatsetaadi kasutamine, farmatseutiline kompositsioon, doseerimishik ja pakend

Country Status (30)

Country Link
US (2) US20010034340A1 (et)
EP (1) EP1265616B1 (et)
JP (1) JP2003527416A (et)
KR (1) KR100805648B1 (et)
CN (1) CN1239160C (et)
AR (1) AR031563A1 (et)
AT (1) ATE326227T1 (et)
AU (2) AU5003401A (et)
BG (1) BG66075B1 (et)
BR (1) BR0109334A (et)
CA (1) CA2402983A1 (et)
CY (1) CY1105632T1 (et)
CZ (1) CZ20023162A3 (et)
DE (1) DE60119703T2 (et)
DK (1) DK1265616T3 (et)
EA (1) EA005592B1 (et)
EE (1) EE05129B1 (et)
ES (1) ES2261393T3 (et)
HK (1) HK1049449B (et)
HR (1) HRP20020837B1 (et)
HU (1) HUP0302093A3 (et)
IL (1) IL151512A0 (et)
MX (1) MXPA02009116A (et)
NO (1) NO326886B1 (et)
NZ (1) NZ521171A (et)
PL (1) PL201762B1 (et)
PT (1) PT1265616E (et)
SK (1) SK286169B6 (et)
TW (1) TWI271194B (et)
WO (1) WO2001070208A2 (et)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
WO2002074292A2 (en) * 2001-03-16 2002-09-26 Wyeth Hormone replacement therapy
EP1857110A3 (en) * 2001-03-16 2008-08-06 Wyeth Hormone replacement therapy
WO2008150547A1 (en) 2007-06-04 2008-12-11 The Regents Of The University Of California Pregnancy hormone combination for treatment of autoimmune diseases
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
TWI252111B (en) * 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
TW200306846A (en) * 2002-04-03 2003-12-01 Wyeth Corp Hormone replacement therapy
US20030216366A1 (en) * 2002-04-03 2003-11-20 Leonard Thomas W. Step-down estrogen therapy
TW200306196A (en) * 2002-04-03 2003-11-16 Wyeth Corp Hormone replacement therapy
TW200306851A (en) * 2002-04-29 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
CN101406464A (zh) * 2002-06-06 2009-04-15 霍尔莫斯医疗有限公司 抑制女性萎缩或治疗或预防与女性萎缩相关的症状的方法
TW200404548A (en) * 2002-06-25 2004-04-01 Wyeth Corp Pharmaceutical composition containing cyclothiocarbamate derivatives in treatment of hormone-related conditions
MXPA04012419A (es) * 2002-06-25 2005-04-19 Wyeth Corp Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con la hormona.
US8349819B2 (en) 2002-10-09 2013-01-08 Dr. Reddy's Laboratories New York, Inc. Steroid extraction process from urine sources
EP1622623A4 (en) * 2003-04-11 2009-03-18 Barr Lab Inc METHOD FOR THE ADMINISTRATION OF ESTROGENIC AND TESTED
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
AU2006330846A1 (en) 2005-12-27 2007-07-05 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
CA2644913A1 (en) * 2006-04-05 2007-10-18 Wyeth Methods for prevention and treatment of conditions arising from local estrogen deficiency
BRPI0719675A2 (pt) * 2006-11-29 2013-12-24 Wyeth Corp Comprimido com bicamada de estrogênio/serm e estrogênio/progestina
WO2008099060A2 (en) * 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
BRPI0807675B1 (pt) * 2007-02-14 2021-05-18 Hormos Medical Ltd. método para a preparação de um composto derivado de trifenilbuteno
KR100989093B1 (ko) 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
US9734496B2 (en) 2009-05-29 2017-08-15 Paypal, Inc. Trusted remote attestation agent (TRAA)
WO2011097571A2 (en) * 2010-02-08 2011-08-11 Prairie Pharmaceuticals, Llc Methods for the use of progestogen as a glucocorticoid sensitizer
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11224603B2 (en) * 2013-12-13 2022-01-18 Requis Pharmaceuticals, Inc. Antihistamines in combination with a range of substances for improved health
WO2015168000A1 (en) 2014-04-28 2015-11-05 The Regents Of The University Of California Estrogen combination for treatment of multiple sclerosis
EP3137088B1 (en) 2014-04-28 2023-08-30 The Regents of The University of California Pharmaceutical packaging for estriol therapy for the treatment of multiple sclerosis
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10821117B2 (en) 2014-09-02 2020-11-03 The Regents Of The University Of California Estrogen therapy for brain gray matter atrophy and associated disability
EP3200802B1 (en) * 2014-09-29 2023-07-12 The Regents of The University of California Compositions and methods for maintaining cognitive function
EP3277285B1 (en) 2015-03-30 2024-07-17 The Regents of the University of California Estriol for reducing cortical gray matter atrophy
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2020081726A1 (en) * 2018-10-17 2020-04-23 Stadler Sarah Sheehan Methods of treating menopausal symptoms using low dose progesterone
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU582540B2 (en) * 1983-08-05 1989-04-06 Pre Jay Holdings Ltd. A method of hormonal treatment of perimenopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
ATE209919T1 (de) * 1987-09-24 2001-12-15 Jencap Res Ltd Oestrogen und progestin enthaltende verhütungspackungen
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings

Also Published As

Publication number Publication date
DK1265616T3 (da) 2006-06-12
TWI271194B (en) 2007-01-21
BG66075B1 (en) 2011-02-28
HUP0302093A2 (hu) 2003-10-28
AU2001250034B2 (en) 2005-03-24
HK1049449A1 (en) 2003-05-16
NZ521171A (en) 2004-09-24
SK286169B6 (sk) 2008-04-07
US20010034340A1 (en) 2001-10-25
US20090005351A1 (en) 2009-01-01
NO20024478D0 (no) 2002-09-19
KR100805648B1 (ko) 2008-02-26
PL363157A1 (en) 2004-11-15
HRP20020837B1 (hr) 2007-08-31
CA2402983A1 (en) 2001-09-27
MXPA02009116A (es) 2003-03-12
HRP20020837A2 (en) 2004-02-29
ATE326227T1 (de) 2006-06-15
CN1418102A (zh) 2003-05-14
NO20024478L (no) 2002-09-19
WO2001070208A3 (en) 2002-04-25
ES2261393T3 (es) 2006-11-16
CN1239160C (zh) 2006-02-01
IL151512A0 (en) 2003-04-10
AU5003401A (en) 2001-10-03
DE60119703D1 (de) 2006-06-22
KR20020084230A (ko) 2002-11-04
EA200201000A1 (ru) 2003-02-27
EE200200535A (et) 2004-04-15
HUP0302093A3 (en) 2010-03-29
SK13482002A3 (sk) 2003-02-04
BR0109334A (pt) 2002-12-24
AR031563A1 (es) 2003-09-24
BG107095A (bg) 2003-05-30
EP1265616B1 (en) 2006-05-17
NO326886B1 (no) 2009-03-16
WO2001070208A2 (en) 2001-09-27
JP2003527416A (ja) 2003-09-16
DE60119703T2 (de) 2006-10-19
EA005592B1 (ru) 2005-04-28
CY1105632T1 (el) 2010-12-22
PL201762B1 (pl) 2009-05-29
EP1265616A2 (en) 2002-12-18
HK1049449B (en) 2006-07-28
CZ20023162A3 (cs) 2003-03-12
PT1265616E (pt) 2006-08-31

Similar Documents

Publication Publication Date Title
EE05129B1 (et) Konjugeeritud ”strogeenide ja medroksprogesteroonatsetaadi kasutamine, farmatseutiline kompositsioon, doseerimishik ja pakend
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
EE05081B1 (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
EE200300240A (et) Arüülitud furaan- ja tiofeenkarboksamiid, seda sisaldav ravimpreparaat ning ühendi kasutamine kaaliumikanali blokaatorina toimiva ravimi valmistamiseks
EE04965B1 (et) Imidasoimidasoolid ja triasoolid kui p?letikuvastased hendid, nende kasutamine ravimite valmistamiseks ning farmatseutiline kompositsioon
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE200200487A (et) Asetidiini derivaadid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
NO20020464D0 (no) Flerkomponent-farmasöytisk doseringsform
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
EE200200522A (et) Toimeainega konjugeerunud ensüüm-lõhustuv peptiid, seda sisaldav farmatseutiline kompositsioon ningühendi kasutamine kasvajavastase ravimina
EE200100391A (et) Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon
EE04997B1 (et) Loteprednooli ja antihistamiinseid aineid sisaldav farmatseutiline kompositsioon, neid aineid sisaldav ravim, meetod selle ravimi valmistamiseks ja nende ainete kombinatsiooni kasutamine
EE200200075A (et) Peroraalselt ja paikselt manustatavad farmatseutilised kompositsioonid
AR028023A1 (es) Una composicion farmaceutica para el tratamiento de la hiperlipidemia y el uso de dicha composicion para la preparacion de medicamentos
BR0012184B1 (pt) compostos derivados de indol, formulação farmacêutica, e, composição e uso dos compostos na fabricação de medicamentos
EE200200551A (et) Oligosahhariide sisaldav farmatseutiline kompositsioon, oligosahhariidid, nende valmistamine ja raviotstarbeline kasutamine
EE200200480A (et) Memnopeptiidühend, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
DE60139306D1 (de) N-deacetylthiocolchin-derivate und diese enthaltende arzneimittel
EE200300436A (et) Imidasolidiini derivaadid, nende valmistamine ja kasutamine põletikuvastaste toimeainetena ning neid sisaldav ravimpreparaat
FI20011192A0 (fi) Flavonoidilääkeaine ja annostusmuoto, sen valmistus ja käyttö
HU0303147D0 (en) Pharmaceutical compositions for oral and topical administration
HUP0004153A3 (en) 3-amino-triazole derivatives with medicinal applicability, process for their preparation and pharmaceutical compositions containing them and their use
DE60234604D1 (de) Orale dosierungsform enthaltend einen therapeutischen wirkstoff und einen gegenwirdenden wirkstoff
EE05031B1 (et) Diarlennid, kompositsioon, farmatseutiline kompositsioon ja diarlennide kasutamine

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20120316